• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

安替比林在两种肝硬化大鼠模型中的体内代谢。其与体外内在清除率及微粒体膜脂质组成的关系。

Metabolism of antipyrine in vivo in two rat models of liver cirrhosis. Its relationship to intrinsic clearance in vitro and microsomal membrane lipid composition.

作者信息

Buters J T, Zysset T, Reichen J

机构信息

Department of Clinical Pharmacology, University of Berne, Switzerland.

出版信息

Biochem Pharmacol. 1993 Sep 14;46(6):983-91. doi: 10.1016/0006-2952(93)90662-g.

DOI:10.1016/0006-2952(93)90662-g
PMID:8216358
Abstract

Antipyrine metabolism depends on at least three isoenzymes of cytochrome P450 forming the main metabolites 3-OH-, 4-OH- and norantipyrine. We investigated to what extent antipyrine clearance and metabolite formation are impaired in two models of liver cirrhosis in the rat, namely micronodular cirrhosis induced by chronic exposure to phenobarbital/CCl4 and biliary cirrhosis induced by bile duct ligation. Salivary antipyrine clearance was decreased to a similar extent in cirrhosis induced by CCl4 and bile duct ligation (-35%). Clearance for production of 3-OH-antipyrine was decreased in both models, while 4-hydroxylation was maintained. Metabolic clearance of both 3-OH-antipyrine and 4-OH-antipyrine in vivo correlated with their clearance in vitro (r = 0.658 and r = 0.583) but not with that of norantipyrine. The microsomal cholesterol content was increased by 16% and 90% in CCl4 and bile duct-ligated cirrhotic rats (P < 0.001), respectively. Membrane fluidity, expressed as the ratio of phospholipids to cholesterol, correlated with the in vivo clearance for production of norantipyrine (r = 0.841) but not of 3-OH- or 4-OH-antipyrine, while clearance in vitro was not related to altered lipid composition. Our results demonstrate that the cytochrome P450 isoenzymes responsible for the different pathways of antipyrine metabolism are affected to different extents by cirrhosis. Alterations in intrinsic clearance explain only part of the loss of hepatocellular function. Altered lipid composition contributes to this loss of function but other factors, among them loss of hepatocytes and changes in microcirculation, could be more important determinants of the decrease in xenobiotic metabolism in cirrhosis.

摘要

安替比林代谢至少依赖于细胞色素P450的三种同工酶,它们形成主要代谢产物3 - 羟基 - 、4 - 羟基 - 和去甲安替比林。我们研究了在大鼠肝硬化的两种模型中,安替比林清除率和代谢产物形成受损的程度,这两种模型分别是慢性暴露于苯巴比妥/CCl4诱导的小结节性肝硬化和胆管结扎诱导的胆汁性肝硬化。在CCl4和胆管结扎诱导的肝硬化中,唾液安替比林清除率下降程度相似(-35%)。两种模型中3 - 羟基安替比林生成的清除率均下降,而4 - 羟化作用得以维持。体内3 - 羟基安替比林和4 - 羟基安替比林的代谢清除率与其体外清除率相关(r = 0.658和r = 0.583),但与去甲安替比林的清除率无关。在CCl4和胆管结扎的肝硬化大鼠中,微粒体胆固醇含量分别增加了16%和90%(P < 0.001)。以磷脂与胆固醇的比值表示的膜流动性与去甲安替比林生成的体内清除率相关(r = 0.841),但与3 - 羟基 - 或4 - 羟基安替比林的清除率无关,而体外清除率与脂质组成改变无关。我们的结果表明,负责安替比林不同代谢途径的细胞色素P450同工酶受肝硬化影响的程度不同。内在清除率的改变仅部分解释了肝细胞功能的丧失。脂质组成的改变促成了这种功能丧失,但其他因素,包括肝细胞丢失和微循环变化,可能是肝硬化中外源性物质代谢减少的更重要决定因素。

相似文献

1
Metabolism of antipyrine in vivo in two rat models of liver cirrhosis. Its relationship to intrinsic clearance in vitro and microsomal membrane lipid composition.安替比林在两种肝硬化大鼠模型中的体内代谢。其与体外内在清除率及微粒体膜脂质组成的关系。
Biochem Pharmacol. 1993 Sep 14;46(6):983-91. doi: 10.1016/0006-2952(93)90662-g.
2
Sex difference in antipyrine 3-hydroxylation. An in vivo-in vitro correlation of antipyrine metabolism in two rat strains.安替比林3-羟基化的性别差异。两种大鼠品系中安替比林代谢的体内-体外相关性。
Biochem Pharmacol. 1990 Aug 15;40(4):771-7. doi: 10.1016/0006-2952(90)90314-b.
3
Abnormal lipid composition of microsomes from cirrhotic rat liver--does it contribute to decreased microsomal function?肝硬化大鼠肝脏微粒体的脂质组成异常——这是否导致微粒体功能下降?
Experientia. 1992 May 15;48(5):482-6. doi: 10.1007/BF01928168.
4
Differential effect of biliary and micronodular cirrhosis on oxidative drug metabolism. In vivo-in vitro correlations of dextromethorphan metabolism in rat models.胆汁性肝硬化和小结节性肝硬化对氧化药物代谢的差异影响。大鼠模型中右美沙芬代谢的体内-体外相关性。
Biochem Pharmacol. 1991 May 15;41(10):1513-9. doi: 10.1016/0006-2952(91)90569-q.
5
Stereological and functional analysis of liver mitochondria from rats with secondary biliary cirrhosis: impaired mitochondrial metabolism and increased mitochondrial content per hepatocyte.继发性胆汁性肝硬化大鼠肝脏线粒体的体视学和功能分析:线粒体代谢受损及每个肝细胞线粒体含量增加。
Hepatology. 1992 Jun;15(6):1167-72. doi: 10.1002/hep.1840150631.
6
Antipyrine clearance and metabolite formation in primary biliary cirrhosis.
Dig Dis Sci. 2001 Feb;46(2):352-9. doi: 10.1023/a:1005661117739.
7
The effect of age on antipyrine metabolism by liver microsomes isolated from phenobarbital-treated rats.
Mech Ageing Dev. 1989 Sep;49(3):287-94. doi: 10.1016/0047-6374(89)90079-1.
8
Effect of development on the functional and histological changes induced by bile-duct ligation in the rat.发育对大鼠胆管结扎诱导的功能和组织学变化的影响。
J Hepatol. 1994 Feb;20(2):231-9. doi: 10.1016/s0168-8278(05)80063-7.
9
Clearance by the liver in cirrhosis. I. Relationship between propranolol metabolism in vitro and its extraction by the perfused liver in the rat.肝硬化时肝脏的清除率。I. 大鼠体外普萘洛尔代谢与其经灌注肝脏摄取之间的关系。
Hepatology. 1993 Feb;17(2):301-6.
10
The effect of endothelin and its antagonist Bosentan on hemodynamics and microvascular exchange in cirrhotic rat liver.内皮素及其拮抗剂波生坦对肝硬化大鼠肝脏血流动力学及微血管交换的影响。
J Hepatol. 1998 Jun;28(6):1020-30. doi: 10.1016/s0168-8278(98)80352-8.

引用本文的文献

1
Effects of membrane transport activity and cell metabolism on the unbound drug concentrations in the skeletal muscle and liver of drugs: A microdialysis study in rats.膜转运活性和细胞代谢对药物在骨骼肌和肝脏中游离药物浓度的影响:大鼠微透析研究。
Pharmacol Res Perspect. 2021 Oct;9(5):e00879. doi: 10.1002/prp2.879.
2
Pharmacokinetics of phenazone (antipyrine) in rabbits with experimental common bile duct obstruction.非那宗(安替匹林)在实验性胆总管梗阻家兔体内的药代动力学
Br J Pharmacol. 1996 Jan;117(1):1-4. doi: 10.1111/j.1476-5381.1996.tb15146.x.
3
Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update.
肝病患者的临床药代动力学和药效学考量。最新进展。
Clin Pharmacokinet. 1995 Nov;29(5):370-91. doi: 10.2165/00003088-199529050-00005.